Bayer, one of the world’s largest pharmaceutical companies, announced on Friday that it will be shifting its focus away from women’s health.
The company plans to put more research efforts into rare diseases, cardiovascular disease, neurology, oncology and immunology.
“When it comes to research and the subsequent clinical phases, we will no longer have an explicit focus on women’s health,” the head of Bayer’s pharmaceuticals unit, Stefan Oelrich, told Reuters.
However, the company — which makes the common consumer drugs Aleve, Midol, MiraLAX, Alka-Seltzer and Claritin — will continue development of elinzanetant, a non-hormonal medication intended to treat menopausal symptoms.